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Dendritic cells (DCs) from NOD mice produced high levels of IL-12 that induce IFNγ-producing T cells involved in diabetes
development. We propose to utilize the microorganism ability to induce tolerogenic DCs to abrogate the proinﬂammatory process
and prevent diabetes development. NOD DCs were stimulated with Lactobacilli (nonpathogenic bacteria targeting TLR2) or
lipoteichoic acid (LTA) from Staphylococcus aureus (TLR2 agonist). LTA-treated DCs produced much more IL-12 than IL-10 and
accelerated diabetes development when transferred into NOD mice. In contrast, stimulation of NOD DCs with L. casei favored the
production of IL-10 over IL-12, and their transfer decreased disease incidence which anti-IL-10R antibodies restored. These data
indicated that L. casei can induce NOD DCs to develop a more tolerogenic phenotype via production of the anti-inﬂammatory
cytokine, IL-10. Evaluation of the relative production of IL-10 and IL-12 by DCs may be a very useful means of identifying agents
that have therapeutic potential.
1.Introduction
Proinﬂammatory cytokines are increased during the active
stages of type 1 diabetes and appear to be involved in disease
development in NOD mice [1, 2]. DCs and macrophages
fr o mN ODm i c eh a v ebee ns h o wnt op r od uc eh i gh e rl ev el so f
proinﬂammatory cytokines, including IL-12 (p70) and TNF-
α [3–5] ,a sar e s u l to fN F κBh y p e r a c t i v i t y[ 6–9]b yc o m p a r -
ison to diabetes-resistant strains of mice, that is, C57BL/6,
BALB/c, and NOR [6]. Moreover, myeloid DCs cultured
from NOD bone marrow or spleen exhibit hyperactivation
of NFκB in response to several stimuli [8]. Taken together,
thesedatastronglysuggestthatadefectinregulationofNFκB
activationexistsinNODDCsandmacrophagesandmayplay
a key role in the modulation of APC function in NOD mice.
Similarly, elevated IL-12 production as well as polymor-
phisms in the region of the IL-12 gene has also been associ-
ated with individuals at high risk for type 1 diabetes [10, 11].
The increase in IL-12 in NOD mice is particularly signiﬁcant
since it leads to activation of IFNγ-producing T cells which
can mediate disease development [1, 2, 12]. Furthermore,
suppression of IL-12 in NOD mice has been shown to reduce
cellular inﬁltration in islets and prevent the development of
diabetes [13]. Therefore, switching the cytokine proﬁle of
NOD DCs from proinﬂammatory to anti-inﬂammatory may
be an eﬀective strategy to abrogate activation of pathogenic
Th1 cells and prevent diabetes development, since DCs have
beenshowntoorchestratethedelicatebalancebetweenT-cell
immunity and regulation in NOD mice [14].
Bacteria isolated from the normal gut ﬂora are non-
pathogenic and include the Lactobacillus species. Various
strains of Lactobacilli, including L. casei, L. reuteri, and L.
plantarum, have been shown to prevent diabetes [15, 16],
collagen-induced arthritis [17], and colitis [18, 19] in animal
models. In addition, Lactobacilli have been used to manage
allergic diseases and are associated with improvement of
various gastrointestinal diseases in humans [20, 21]. Recent
studies have shown that various types of microorganisms,2 Clinical and Developmental Immunology
including bacteria, fungi, and parasites, can evade the
immunesystembyinducingtolerogenicAPC[22–24]and/or
regulatory T cells [23, 25–28]. Some of these microor-
ganisms, including Lactobacilli, elicit an anti-inﬂammatory
response, at least in part, via Toll-like Receptor 2 (TLR2)
ligation [26, 29, 30]. Components of microbial cell walls
that target TLR2 have also been found to induce DCs from
nonautoimmune-prone mice to produce anti-inﬂammatory
cytokines and induce regulatory cells [29, 31–33]. There is
a possibility, therefore, that stimulation of NOD DCs with
Lactobacilli or TLR2 ligands could polarize them toward
an anti-inﬂammatory phenotype that could protect against
disease development. We propose that cytokine proﬁles,
particularly IL-12 and IL-10, could be useful predictors of
the ability of stimuli to induce DCs that may be used as a
treatmentforthepreventionofdiabetes.Inthecurrentstudy,
we tested a TLR2 agonist, lipoteichoic acid (LTA), derived
from S. aureus, and three diﬀerent strains of Lactobacilli
for their ability to switch the NOD DCs phenotype to an
anti-inﬂammatory tolerogenic phenotype. We report in the
present paper that transfer of BM-DCs induced to produce
IL-10 into NOD mice delayed onset and decreased incidence
of diabetes, whereas transfer of BM-DCs induced to produce
IL-12 has the opposite eﬀect, that is, an acceleration in
diabetes onset and increase in incidence of diabetes.
2.MaterialsandMethods
2.1. Mice. Female C57BL/6 and NOD mice were obtained
from Jackson Laboratory (Bar Harbor, ME) and maintained
at the University of Louisville facility according to institu-
tional animal care and use committee (IACUC) guidelines.
Mice were anaesthetized with bromoethanol before euthana-
sia in order to harvest organs.
2.2. Antibodies and Flow Cytometry. FITC-anti-B7-1, FITC-
anti-B7-2, PEcy7-anti-CD11b, and PE-anti-CD11c antibod-
ies were purchased (BD Pharmingen, San Diego, CA). Cells
were incubated with Fc block then labeled with antibodies
for20mininDPBS1%FCS,0.1%NaNO3 andwashedtwice.
Cells were analyzed by FACS using a FACScalibur (Becton
Dickinson, Palo Alto, CA).
2.3. Generation of Bone-Marrow-Derived Dendritic Cells.
Bone-marrow-derived dendritic cells (BM-DCs) were gen-
erated by culturing bone marrow cells for 12 days with
Granulocyte-Monocyte Colony Stimulating Factor (GM-
CSF)(PeproTech,RockyHill,NJ)insupercompletemedium
containing RPMI (Mediatech, Herndon, VA) supplemented
with 1% Hepes buﬀer (MP Biomedicals, LLC, Solon,
OH), 1% sodium pyruvate, 1% L-glutamine, 1% penicillin-
streptomycin, 1% nonessential amino acids (Mediatech,
Herndon, VA), 0.1% β2-mercaptoethanol (Sigma-Aldrich,
Saint-Louis, MO), and 10% fetal calf serum (FCS) (Hyclone,
Logan,UT).Brieﬂy,5 ×106 bonemarrowcellswerecultured
in large petri dishes (Nunc, Roskilde, Denmark) in 10mL
of culture medium containing 5ng/mL of GM-CSF. New
culture medium (10mL) was added to the petri dishes at
d a y4 .A td a y s6a n d9 ,h a l fo ft h eo l dc e l lc u l t u r em e d i u m
(10mL) was removed from each petri dish and replaced by
new culture medium containing GM-CSF (5ng/mL), and at
d a y1 2 ,c e l l sw e r eh a r v e s t e d .
2.4. Lactobacilli Cultures. The following Lactobacilli strains
were used: human Lactobacillus reuteri DSM 2016 (DSMZ,
Braunschweig, Germany), human Lactobacillus plantarum
LP299v (PROBI, Lund, Sweden), and human Lactobacillus
casei B255 (NIZO, Ede, The Netherlands). Lactobacilli were
grown on deMan-Rogosa-Sharp (MRS) media (Difco Lab-
oratories, Detroit, MI) under anaerobic conditions, and a
single colony was expanded in MRS broth (Difco Labora-
tories, Detroit, MI) under anaerobic conditions and frozen
in glycerol. Lactobacilli were thawed twice a week and grown
for 20hrs in MRS broth under anaerobic conditions, then
expanded in large quantities until they reached the postex-
ponential phase, that is, 12–16hrs, depending on the strain.
2.5. Dendritic Cell Stimulation and Transfer. BM-DCs were
stimulated overnight with diﬀerent stimuli including 1, 10,
or100μg/mLofLPS-freeLipoteichoicAcid(LTA)fromStap-
hylococcus aureus (Invivogen, San Diego, CA), 100ng/mL of
LPS (Invivogen, San Diego, CA), or 10 × 106 CFU/mL, 1 ×
106 CFU/mL (low dose) or 20 × 106 CFU/mL (high dose)
Lactobacilli. The supernatants were harvested and stored
at −20◦C until assayed using quantitative enzyme-linked
immunosorbent assay (ELISA) kits (eBioscience, San Diego,
CA) according to the manufacturer’s instructions. For the
in vivo experiments, gentamycin 10μg/mL was included in
the culture containing Lactobacilli to eliminate any living
bacteria, and the BM-DCs harvested after 24hrs, washed
twice with HBSS. 1 × 106 treated BM-DCs were transferred
into 6–8-week-old NOD mice (n = 4–11mice/group). In
some experiments, 0.5mg/mouse of anti-IL-10R antibodies
or isotype control (BioXCell, West Lebanon, NH) was
injected once a week for a period of four weeks. Sera were
collected 28hrs following injection and stored at −20◦C
until assayed using ELISA kits (eBioscience, San Diego, CA)
according to the manufacturer’s instructions. Blood glucose
was monitored weekly until 30 weeks of age using blood
gl u c o s es tri p sa n dab l oodgl u c o s em et e r( H o m eDi a gn o s ti c s ,
Inc., Ft Lauderdale, FL). Mice were considered diabetic when
glucose levels were >300mg/dl for two consecutive weeks.
2.6. Statistical Analysis. Data were analyzed using either the
Student’s t-test, Wilcoxon test, or nonparametric log-rank
test. Each experiment was repeated with reproducible results
2–4 times.
3. Results
3.1. Eﬀect of a TLR-2 Ligand on NOD BM-DCs Activation
and Phenotype. Antigen presenting cells (APCs) from adult
N O Dm i c eh a v eb e e ns h o w nt op r o d u c eh i g hl e v e l so f
the proinﬂammatory cytokine, IL-12 [3–5]i nr e s p o n s et o
LPS and express lower levels of costimulatory molecules
such as B7-1 and B7-2 [34, 35]. The overproduction of IL-
12 by NOD APC is thought to contribute signiﬁcantly to
disease development, since it leads to activation of IFNγ-
producing T cells which mediate diabetes [1, 2, 12]. BecauseClinical and Developmental Immunology 3
TLR2 agonists have been shown to induce production
of anti-inﬂammatory cytokines in nonautoimmune mice
and healthy human [29, 31–33], we examined whether a
TLR2 ligand, lipoteichoic acid (LTA) can induce an anti-
inﬂammatory (tolerogenic) phenotype in NOD DCs. We
compared cytokine production and costimulatory molecule
expression by bone-marrow-derived dendritic cells (BM-
DCs) from NOD and B6 mice after stimulation with LTA
isolated from Staphylococcus aureus (S. aureus).D C sw e r e
cultured either in media (none), or in the presence of
10μg/mL of LPS-free LTA or 100ng/mL of LPS. After
24hrs, supernatants were collected and measured for the
presence of the anti-inﬂammatory cytokine, IL-10, or the
proinﬂammatory cytokine, IL-12, by ELISA. As reported
previously, upon stimulation with LPS, NOD DCs produced
considerably more IL-12 than B6 DCs (Figure 1(b))a n d
about the same amount of IL-10 (Figure 1(a)). Surprisingly,
stimulation with LTA from S. aureus also induced NOD DCs
to produce more IL-12 compared to B6 DCs (0.5ng/mL
versus 0.1ng/mL) as shown in Figures 1(a) and 1(b).
Although IL-10 production upon LTA stimulation was about
the same or even a bit higher in NOD DCs compared to B6
DCs (0.18ng/mL versus 0.12ng/mL), the production of IL-
12relativetoIL-10wasmuchgreaterinNODDCscompared
to B6 DCs (Figures 1(a) and 1(b)). Moreover, fewer NOD
DCs expressed B7-1 and B7-2 in response to LTA and LPS
compared to B6 DCs, and the level of expression of B7-2 was
also lower in NOD DCs. In summary, the TLR2 ligand, LTA,
had a diﬀerential eﬀect on the cytokine proﬁle produced by
NOD and B6 DCs: LTA induced more IL-12 than IL-10 in
NOD DCs while inducing the same quantity of IL-12 and IL-
10 in B6 DCs.
3.2. Eﬀect of LTA-Treated BM-DCs on Diabetes Development
in NOD Mice. Since the data described above suggested that
LTA from S. aureus promotes a more proinﬂammatory than
tolerogenic phenotype in NOD BM-DCs, we examined the
relationship between cytokine production by DCs and dis-
ease development. BM-DCs from NOD mice were cultured
in the absence (none or no treatment) or in the presence
of LTA from S. aureus (LTA-treated NOD DCs) for 24hrs.
Supernatants and cells were harvested, and supernatants
tested for the presence of IL-12 and IL-10. DCs from these
cultures were injected into 6-week-old NOD mice and dis-
ease incidence was assessed. Similar to the results displayed
in Figure 1(a),L T Af r o mS. aureus induced much more IL-
12 than IL-10 production (IL-12:IL-10 ratio of 6.6) by NOD
BM-DCs(datanotshown).Interestingly,100%ofNODmice
injected with LTA-treated NOD DCs developed diabetes by
15 weeks of age (Figure 2(a), open circles) indicating that a
single injection of LTA-treated NOD DCs could signiﬁcantly
accelerate disease onset. Moreover, we found that the level
of IL-12 was higher in the serum of mice injected with
LTA-treated NOD DCs (Figure 2(b), left panel), whereas the
level of IL-10 was not signiﬁcantly diﬀerent (Figure 2(b)).
Because various concentrations of LTA could aﬀect DCs
diﬀe r e n t i a l l y ,w et e s t e dal o w e ra sw e l la sah i g h e rd o s eo f
LTA. As shown in Figure 2(c), DCs treated with 1μg/mL,
10μg/mL or 100μg/mL of LTA and injected into young NOD
mice accelerated diabetes development in a similar manner.
Altogether, these data suggest that injection of LTA-treated
NOD DCs may contribute to diabetes pathogenesis by pro-
ducing high levels of the proinﬂammatory cytokine, IL-12.
3.3. Treatment with Diﬀerent Strains of Lactobacilli Induces
NOD DCs to Produce Diﬀerent Cytokine Proﬁles. Dendritic
cells play a pivotal role in the diﬀerentiation of Th1, Th2,
Th3, and regulatory T cells throughout the gastrointesti-
nal tract [36]. Lactobacilli are bacteria that compose the
normal ﬂora, and feeding Lactobacilli has been shown to
be protective in various models of autoimmune diseases,
including type 1 diabetes [15, 16], collagen-induced arthritis
[17], and colitis [18, 19]. It is thought that Lactobacilli
mediate their protective eﬀect by modulating DCs cytokine
production and surface molecule expression [37]. We tested
the eﬀects of stimulating NOD and B6 DCs with three
diﬀerent strains of Lactobacilli on cytokine production and
costimulatorymoleculeexpressioninordertoassesswhether
there were any diﬀerences in the ability of these strains
to induce anti-inﬂammatory phenotypes in NOD DCs.
These three strains included Lactobacillus casei (L. casei),
Lactobacillus plantarum (L. plantarum), and Lactobacillus
reuteri (L. reuteri) and were selected based on their ability to
induce tolerance [38] or prevent disease in animal models,
including diabetes [16], arthritis [17, 39], and colitis [18,
19]. We examined the production of the proinﬂammatory
cytokine, IL-12, and anti-inﬂammatory cytokine, IL-10, by
NOD and B6 BM-DCs stimulated with each of the strains of
Lactobacillidescribedabovefor24hrs.Interestingly,cytokine
production varied dramatically depending on the strain of
Lactobacilli used and the source of DCs, that is, NOD versus
B6 mice (Figures 3(a) and 3(b)). L. reuteri induced NOD
BM-DCs to produce the highest level of IL-12 (Figure 3(a),
fourth black column) and among the lowest levels of IL-
10 (Figure 3(a), fourth white column), with IL-12 produced
about an 11-fold higher level than IL-10. L. plantarum
induced a low to intermediate level of IL-12 and a very
low level of IL-10 in NOD BM-DCs, and IL-12 production
(Figure 3(a), third black column) was about 3-fold higher
than IL-10 production (Figure 3(a), third white column).
In contrast, L. casei not only induced NOD BM-DCs to
produce the highest level of IL-10 (Figure 3(a),s e c o n dw h i t e
column), but also the lowest level of IL-12 (Figure 3(a),
second black column), and four times more IL-10 than IL-
12 was produced. Interestingly, IL-10 production was much
higher, in general, in B6 DCs stimulated with all three strains
of Lactobacilli,w i t hL. casei inducing the highest levels of IL-
10 and the lowest levels of IL-12 (Figure 3(b)). As shown
in Figures 3(c) and 3(d), all three strains of Lactobacilli
induced approximately the same percentages of NOD BM-
DCs to express B7-1 and B7-2, but to a lower extent than B6
BM-DCs. These data suggest that the ability of Lactobacilli
to induce an anti-inﬂammatory versus proinﬂammatory
phenotype in NOD DCs varies according to the strain, and
L. casei appears to be the only strain of the three tested
that induces an anti-inﬂammatory phenotype. Furthermore,
NOD DCs appeared to be much less predisposed to produce
IL-10 in response to Lactobacilli compared to B6 DCs.4 Clinical and Developmental Immunology
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Figure 1:Eﬀect of LTA on NOD andB6DCs cytokine production andsurface marker expression. BM-DCsfromNOD mice were stimulated
in vitro with 10μg/mL of LTA from S. aureus (LTA), 100ng/mL of LPS, or medium alone (—or none). After 24hrs, supernatants were
collected and measured by ELISA for the presence of IL-10 (a) or IL-12 (b), or cells were collected and labeled with anti-CD11c, anti-CD11b,
and anti-B7-1 (c) or anti-B7-2 (d) antibodies, and analyzed by FACS after gating on CD11b+CD11cint cells.Clinical and Developmental Immunology 5
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Figure 2: Incidence of diabetes in NOD mice injected with LTA-treated DCs. BM-DCs from NOD mice were stimulated in vitro overnight
with 10μg/mL of LTA from S. aureus (LTA) or medium alone (none), washed, and one million DCs were injected into six-week-old NOD
mice (n = 5-6), and blood glucose was monitored weekly (a). Sera from pooled NOD mice untreated or injected with DCs treated with LTA
were collected at 28hrs after injection and tested for the presence of IL-12 and IL-10 by ELISA (b). One million DCs untreated or treated
with 1, 10 or 100μg/mL of LTA were injected into six-week-old NOD mice (n = 6–11), and blood glucose was monitored weekly (c). Mice
were considered diabetic when their blood glucose levels were >300dL/mL for 2 consecutive weeks. ∗indicates a signiﬁcant diﬀerence from
the “DC only” or “untreated” group at P<. 01.
3.4. NOD DCs Treated with Diﬀerent Doses of L. casei Produce
Diﬀerent Cytokine Proﬁles and Induce a Diﬀerent DiseaseOut-
come When Injected into NOD Mice. The dose of Lactobacilli
has been shown to strongly inﬂuence the type of cytokine
produced by DCs from B6 mice in vitro [37]. To determine
the eﬀect of dose of L. casei on cytokine production by NOD
DCs,BM-DCsfromNODmicewereculturedeitherinmedia
(none) or in the presence of 1 × 106 CFU/mL (Low-dose)
or 20 × 106 CFU/mL (High dose) of L. casei. After 24hrs,
supernatants were collected and measured for the presence
of IL-10 or IL-12 by ELISA. The high dose of L. casei (LC)
induced much more IL-10 (Figure 4(a), third white column)
than the low dose of LC (Figure 4(a),s e c o n dw h i t ec o l u m n ) ,
and four times more IL-10 than IL-12 (Figure 4(a), third
black column). These data indicate that high-dose LC is
optimal for inducing NOD DCs to produce a more anti-
inﬂammatory and tolerogenic phenotype.
We next examined whether injection of NOD DCs
treated with either a high or low dose of LC into NOD
mice translates into diﬀerent disease outcomes. BM-DCs
f r o mN O Dm i c ew e r ec u l t u r e di nt h ep r e s e n c eo f1×
106 CFU/mL (low LC) or 20 × 106 CFU/mL of L. casei (high
LC). Gentamycin was included in the culture medium, and
no live bacteria were detected at the end of the culture (i.e.,
after 24hrs). After 24hrs, cells were harvested and injected
into6-week-oldNODmiceanddiseaseonsetwasmonitored.
In mice injected with NOD BM-DCs treated with low-
dose LC, 100% of the mice develop diabetes by 18 weeks6 Clinical and Developmental Immunology
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Figure 3: Activation of NOD and B6 DCs with diﬀerent strains of Lactobacilli in vitro. BM-DCs from NOD or control B6 mice were
stimulated for 24hrs with 10 × 106 CFU/mL L. casei (LC), L. plantarum (LP), L. reuteri (LR), or medium alone (none). After 24hrs,
supernatants were collected and measured by ELISA for the presence of IL-10 or IL-12 (a and b), or cells were collected and labeled with
anti-CD11c, anti-CD11b, and anti-B7-1 (c) or anti-B7-2 (d) antibodies, and analyzed by FACS after gating on CD11b+CD11cint cells.Clinical and Developmental Immunology 7
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Figure 4: Eﬀect of diﬀerent doses of L. casei on the proﬁles of IL-10 and IL-12 production by NOD DCs in vitro and disease incidence.
BM-DCs from NOD mice were stimulated with either 1 × 106 CFU/mL (Low LC), 20 × 106 CFU/mL (High LC) of the L. casei or medium
alone (none). After 24hrs, supernatants were collected and measured by ELISA for the presence of IL-10 (white bar) or IL-12 (black bar) (a).
Six-week-old NOD mice were left untreated or received a single i.v. injection of 1 × 106 DCs treated with either low (1 × 106 CFU/mL-low
L C )o rh i g h( 2 0× 106 CFU/mL-high LC) dose of L. casei (LC) (n = 4–6) (b). Blood glucose was measured weekly and diabetes incidence
determined. ∗indicates a signiﬁcant diﬀerence at P<. 05.
of age (Figure 4(b), closed circle). In contrast, NOD mice
injected with NOD DCs treated with high-dose LC exhibited
a delay in disease onset by about 4 weeks (from 17 to 21
weeks of age), as well as a signiﬁcant decrease in diabetes
incidence from 100% to 60% by 30 weeks (Figure 4(b),
open circle). These data suggest that the dose of Lactobacilli
used to stimulate DCs determines the cytokine proﬁle and,
consequently, disease outcome.
3.5. Injection of IL-10-Producing NOD DCs into NOD
M i c eD e c r e a s e sD i a b e t e sI n c i d e n c e .We next tested whether
injections of LC-treated NOD DCs in NOD mice could
actuallypreventdiabetesdevelopmentinanIL-10dependent
manner.WeadministeredoneortwoinjectionsofNODBM-
DCs treated with high-dose LC starting at 6 weeks of age. As
shown in Figures 5(a) and 5(c), injections of LC-treated sig-
niﬁcantly decreased diabetes incidence by about 40% by 30
weeks in comparison to untreated NOD mice. No statistical
diﬀerenceswerefoundbetweentheuntreatedanduntreated-
DCs-injected groups, and one injection was enough to
decrease disease incidence. We next examined the serum
levelsofIL-10inNODmice28hrsafterinjectionofBM-DCs
treated with high doses of L. casei. As shown in Figure 5(b),
NOD mice injected with LC-treated DCs produced higher
levels of IL-10 in serum 28hrs following injection compared
to noninjected NOD mice, suggesting LC-treated BM-DCs
continue to produce IL-10 after injection and IL-10 may
modulate the immune response in vivo.A t6 h r sa f t e r
injection, very low levels of cytokines were detected with no
diﬀerences among the diﬀerent groups (data not shown),
suggesting that cytokine production/accumulation requires
additional time in order to allow diﬀerences to be detected.
We ﬁnally tested whether the production of IL-10 by LC-
treated DCs was responsible for the decrease in diabetes
incidence. NOD mice were injected with anti-IL-10R or
isotype control antibodies for a four-week period and LC-
treated DCs. The treatment with anti-IL-10R antibodies
completely abrogated production of IL-10 detected in the
serum of mice injected with LC-treated DCs (data not
shown). The incidence of disease was not altered in NOD
mice treated with anti-IL-10R antibody only (Figure 5(c),
closed diamond) compared to NOD mice injected with
untreated DCs and treated with isotype control (Figure 5(c),
open triangle) or anti-IL-10R antibody (data not shown).
More importantly, mice injected with LC-treated DCs and
treated with anti-IL-10R antibodies (Figure 5(c), closed
circle) exhibited a higher diabetes incidence than mice
that were injected with LC-treated DCs and treated with
isotype control (Figure 5(c), open circle), indicating that
IL-10 production plays an important role in LC-treated
DCs-mediated protection. Altogether, these data suggest that
injections of LC-treated DCs early in the disease process may
be eﬀective in preventing full-blown disease in a signiﬁcant
proportion of NOD mice, and IL-10 production by DCs may
be useful to predict the eﬀectiveness of the treatment.
4. Discussion
Previous reports have shown that feeding Lactobacilli has
ap r o t e c t i v ee ﬀect in NOD mice [15, 16]. In the current
study, we examined whether stimulation of NOD DCs with
Lactobacilli and subsequent transfer into young NOD mice
could have a similar protective eﬀect, and whether cytokine
proﬁles produced by DCs after stimulation could be a useful8 Clinical and Developmental Immunology
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Figure 5: Injection of Lactobacilli-treated DCs into NOD mice confers some protection. Six-week-old NOD mice received two injections of
1 × 106 DCs treated with high dose (20 × 106 CFU/mL; NOD-high LC) of LC at 6 and 16 weeks of age (n = 4–6) and blood glucose was
measured weekly and diabetes incidence determined (a). Sera from NOD mice uninjected or injected with DCs treated with high-dose LC
(high LC) were collected at 28hrs after injection, and tested for the presence of IL-10 by ELISA (b). Six-week-old NOD mice left uninjected
or injected with 1 × 106 untreated DCs (n = 4-5) or DCs treated with high dose of LC (n = 4) received anti-IL-10R or isotype control
antibodies, and blood glucose was measured weekly and diabetes incidence determined (c). ∗indicates a signiﬁcant diﬀerence at P<. 03.
predictor of treatment eﬃcacy. We found that stimulation
of NOD DCs with three diﬀerent strains of Lactobacilli
induced upregulation of costimulatory molecules, but had
diﬀerential eﬀects on cytokine production. L. casei induced
production of higher levels of IL-10 while L. reuteri and
L. plantarum induced higher levels of IL-12, corroborating
previous ﬁndings showing that diﬀerent strains of Lacto-
bacilli diﬀerentially modulate expression of cytokines in DCs
from B6 (diabetes-resistant) mice [37]. Injection of IL-10-
producing NOD DCs stimulated with L. casei signiﬁcantly
decreased disease incidence. Surprisingly, NOD DCs treated
with the TLR2 agonist, lipoteichoic acid (LTA) produced
large amounts of IL-12 and accelerated diabetes onset and
increased disease incidence upon transfer into NOD mice.
These data indicate that NOD DCs can be manipulated to
become tolerogenic, and that the cytokine proﬁle elicited can
predict the ability of these cells to prevent diabetes upon
injection into NOD mice.
NOD DCs have been shown to express lower levels of
costimulatory molecules, such as B7 [35], and in the current
study, we found that stimulation with Lactobacilli restored
normal levels of B7-1 and B7-2 expression on the surface of
NOD DCs, suggesting that Lactobacilli can induce NOD DCs
maturation. The upregulation of B7 on NOD DCs following
Lactobacilli treatment is particularly signiﬁcant, since B7
has been found to be important for regulation of diabetes
[40], and regulatory cell development and homeostasis [41,
42]. On one hand, treatment of NOD mice with anti-B7-1
antibodies accelerated diabetes development, suggesting that
B7-1 may be associated with induction of regulatory cells
that control diabetes development [40]. On the other hand,
treatment with anti-B7-2 antibodies prevented diabetes,Clinical and Developmental Immunology 9
implicating B7-2 in disease pathogenesis [40] .T h e r ei sa
possibility that expression of B7-1 and B7-2 by diﬀerent
antigen-presenting cells play diﬀerent and opposing roles.
Expression of B7-1 on DCs may play a unique role in regu-
latory cell induction, since DCs are very potent activators of
regulatorycellsthatcancontroldiabetes[43,44].Incontrast,
expression of B7-2 on B cells may be very important for
diabetes induction, since B cells have been shown to be cru-
cial for diabetes development and are excellent inducers of
IFNγ-producing T cells that respond to pancreatic antigens
[45–47]. Expression of B7-2 on DCs may, therefore, not
necessarily be associated with pathogenicity in NOD mice.
Furthermore, the cytokines produced by DCs may be
more crucial in determining the status of the DCs in terms
of their immunogenicity versus tolerogenicity despite the
expression of costimulatory molecules. We have found that
a single injection of LC-treated DCs is suﬃcient to aﬀect
diabetes development. Several studies have reported decrease
in diabetes incidence following one injection of DCs whose
cytokine proﬁle was modulated to produce IL-10 and not IL-
12 [48–50]. Since the lifespan of DCs, once injected in vivo,
is around 12–15 days, it is safe to assume that these DCs
may be able to promote long-term tolerance or immunity
according to their cytokine production proﬁles. Indeed, IL-
10-producing mature DCs expressing high levels of B7-1 and
B7-2 have been shown to induce the development of Tr1 cells
that can inhibit inﬂammation in a model of asthma [51].
A recent study has also shown that injection of GM-CSF
into prediabetic NOD mice prevents diabetes development
by inducing IL-10-producing tolerogenic DCs that sustain
the suppressive function of CD4+CD25+ regulatory T cells
[52]. Similarly, DCs harvested from the pancreatic LN of
NOD mice do not produce IL-12 and are tolerogenic as
reﬂected by the protection mediated by their transfer [48].
There is also a possibility that a regulatory Th2 response
has been induced after transfer of L. casei-treated DCs as
found previously after transfer of BM-DCs generated in the
presenceofGM-CSF/IL-4[53]orsplenicFlt-3L-derivedDCs
[50]. Conversely, we found that LTA-treated DCs produced
much more IL-12 than IL-10, and without upregulating
high expression of B7-1 or B7-2 accelerated diabetes when
injected into NOD mice. Therefore, our data appear to show
that the proﬁle of cytokines produced by DCs may play
a determinant role in their ability to induce a pathogenic
versus a tolerogenic response.
The role that IL-10 plays in diabetes development in
NOD mice is complex, since IL-10 appears to be involved
in diabetes pathogenesis as well as diabetes prevention. On
the one hand, there is evidence that IL-10 is involved at
some level in diabetes pathogenesis. First, neutralization of
IL-10 with anti-IL-10 antibodies eﬀectively blocks insulitis
development in NOD mice [54]. In addition, the incidence
of diabetes is enhanced in transgenic IL-10-NOD mice
expressing IL-10 in the glucagon-producing α-cells of the
pancreas [55], and adoptive transfers of prediabetic or
diabetic wild-type NOD splenocytes into these transgenic
IL-10-NOD mice accelerates diabetes [56]. Interestingly,
injection of IL-10-deﬁcient NOD splenocytes into transgenic
IL-10-NOD. SCID mice accelerates diabetes, demonstrating
that pancreatic IL-10, not peripheral IL-10, appears to play
a role in diabetes pathogenesis [56]. On the other hand,
IL-10 appears to also play an important role in diabetes
prevention. Intraperitoneal injection of a long-lived noncy-
tolyticmurineIL-10/FcfusionproteinintoyoungNODmice
prevents insulitis and diabetes by blocking the production
of proinﬂammatory cytokines and IFNγ [57], and IL-
10-transduced islet-speciﬁc CD4+ T-cells prevent diabetes
transfer in NOD mice [58]. Furthermore, systemic delivery
of IL-10 by intramuscular injection of expression plasmid
DNA can prevent diabetes in NOD mice [59]. Finally,
prevention of diabetes by injection of IL-10 expressing vector
intoNODmiceisassociatedwithanincreaseinCD4+CD25+
regulatory T cells [60]. Taken together, these data, and
our data suggest that timing, location, n and concentration
of IL-10 may determine whether IL-10 is protective or
disease exacerbating. Our data suggest that IL-10 produced
by Lactobacilli- t r e a t e dN O DB M - D C si si n v o l v e di nt h e
protection observed in our model system and could be
having a direct impact or acts via induction of regulatory T
cells as shown previously [60, 61]. We attempted to block
the protective eﬀect induced by Lactobacilli-treated NOD
DCs injected into NOD mice using anti-IL10R antibodies in
vivo. There was a decrease in protection in mice treated with
the anti-IL-10R antibodies when compared to mice treated
with isotype control, conﬁrming a role for IL-10 in diabetes
protection mediated by injection of Lactobacilli-treated DCs.
Although IL10-deﬁcient NOD mice are not readily available,
it would be interesting to test whether BM-DCs from IL-
10-deﬁcient NOD mice are capable of preventing diabetes,
or whether feeding Lactobacilli to IL-10-deﬁcient NOD mice
can still aﬀect diabetes development.
Lactobacilli have been shown to mediate their eﬀects
via TLR-2 [30, 62], possibly via Lipoteichoic acid (LTA),
a TLR-2 agonist and one of the main immunostimulatory
components of Lactobacilli bacteria. However, in contrast
to the whole Lactobacillus organism, we have found that
LTA isolated from S. aureus induced NOD BM-DCs to
produce much more IL-12 than IL-10 and upregulated the
expression of B7-1 and B7-2 on the surface of NOD BM-
DCs. Consequently, NOD BM-DCs treated with LTA from S.
aureus failed to protect NOD mice from diabetes and, in fact,
appeared to exacerbate disease. This is not surprising since
IL-12 have been reported to mediate disease development
in NOD mice via activation of T cells producing IFNγ
[2, 12, 13]. Analysis of mutant L. plantarum that exhibit
altered teichoic acid biosynthesis indicates that alteration in
LTA structure correlates with a change in its ability to induce
proinﬂammatory versus anti-inﬂammatory responses [63].
Although we cannot rule out that components other than
LTAmaybeinvolvedintheinductionofIL-10byLactobacilli,
the predominant production of IL-12 versus IL-10 by NOD
BM-DCs stimulated with LTA isolated from S. aureus could
be due to diﬀerences in the structure of LTA by comparison
to Lactobacilli, in general, and could also contribute to the
diﬀerences in cytokine production between the diﬀerent
strains of Lactobacilli [10, 11]. It would be interesting to
determine whether LTA isolated from Lactobacilli behave
diﬀerently than LTA isolated from S. aureus.10 Clinical and Developmental Immunology
5. Conclusions
Our data indicate that transfer of diﬀerentially stimulated
DCs into NOD mice can accelerate or prevent diabetes
development depending on the cytokine proﬁle of the
DCs. Depending on the strain of Lactobacilli and the
dose, DCs can be induced to secrete anti-inﬂammatory
cytokines that appear to mediate some diabetes protection.
The speciﬁc molecular component from Lactobacilli that
aﬀords protection in NOD mice remains unknown. It will,
therefore, be very important to determine the nature of the
putative protective component(s) that preferentially induces
tolerance versus inﬂammation, as well as the signalling
pathways involved in this process. With this knowledge
in hand, it should be possible to design more eﬃcacious
DCs-based therapies capable of completely preventing or
treating disease. Furthermore, by using pancreatic antigens
along with this strategy, it may be possible to generate
tolerogenic DCs that are capable of inducing potent antigen-
speciﬁc regulatory cells and, therefore, are more eﬃcacious
in preventing or treating disease.
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